Radiation-induced lung injury

Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference

Retrieved on: 
星期三, 五月 8, 2024
Hypoxemia, Supplement, Pulmonology, Patient, Adolescence, Inhalation, ATS, Euphoria, Adrenal insufficiency, Cystic fibrosis, Dizziness, AIM, Oxygen saturation (medicine), Doctor of Philosophy, Conference, Research, Bronchopulmonary dysplasia, Radiation-induced lung injury, Heart rate, Ageing, Transience, Headache, RIS, MRI, Magnetic resonance imaging, Hypoesthesia, Government, Asthma, Risk, COVID-19, Orthostatic hypertension, COPD, Medical imaging

The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

Key Points: 
  • The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.
  • The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups.
  • After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd.
  • Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships.

Lung Bronchoscope Finds Unexpected Use at Fort Sanders Regional Medical Center

Retrieved on: 
星期六, 十一月 18, 2023
Badger, Covenant Health, Lung cancer, Life, Congestion, MD, Radiation-induced lung injury, Antibiotics

Varun Shah, MD , an interventional pulmonologist at Fort Sanders Regional Medical Center in Knoxville, TN, recently used robotic bronchoscopy to remove a nail from a man's lung.

Key Points: 
  • Varun Shah, MD , an interventional pulmonologist at Fort Sanders Regional Medical Center in Knoxville, TN, recently used robotic bronchoscopy to remove a nail from a man's lung.
  • Badger still has the nail, a reminder of what could have been a devastating lung injury and a painful procedure.
  • Fort Sanders Regional Medical Center is a member of Covenant Health , a not-for-profit healthcare delivery system serving East Tennessee and the surrounding region.
  • Located in downtown Knoxville, Fort Sanders Regional offers cutting-edge treatments and advanced technology in a multitude of services.

BIO 300 Demonstrates Protection Against Radiation-Induced Lung Injury

Retrieved on: 
星期二, 二月 7, 2023
FDA, Contracts, White House, Federal Government, Radiology, Pharmaceutical, Homeland Security, Defense, Public Policy, Government, Military, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Unitary state, Chronic radiation syndrome, ARS, BIO, Armed Forces Radiobiology Research Institute, Survivor, Department of Defense Serum Repository, Radiation Research, Radiation-induced lung injury, Acute radiation syndrome, Patient, Humanetics, Clinical trial, Fibrosis, United States Department of Defense, MCM, Pegfilgrastim, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Risk, Radiation, Policy, Radiation exposure, Lung cancer, Army, Polish Radiation Research Society, COVID-19, Cancer, Medical imaging, Vaccine

A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from studies conducted with Humanetics Corporation’s (Humanetics) new radioprotective drug, BIO 300, finding that BIO 300 is uniquely effective at protecting against radiation-induced lung injury.

Key Points: 
  • A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from studies conducted with Humanetics Corporation’s (Humanetics) new radioprotective drug, BIO 300, finding that BIO 300 is uniquely effective at protecting against radiation-induced lung injury.
  • Specifically, these nonclinical studies compared the efficacy of BIO 300 to FDA-approved PEGfilgrastim (Neulasta®), and the combination treatment of BIO 300 plus PEGfilgrastim.
  • The researchers concluded that both BIO 300 formulations, as well as the combination of BIO 300 with PEGfilgrastim, demonstrated significant efficacy in preventing radiation-induced lung inflammation and fibrosis, whereas PEGfilgrastim administered alone had minimal impact on such delayed lung injuries.
  • These studies highlight the considerable advantages of BIO 300, which can prophylactically prevent both acute and delayed radiation injuries.

Atossa Therapeutics Issues Letter to Shareholders

Retrieved on: 
星期三, 一月 25, 2023
Exemestane, Breast cancer, Food, Safety, Patient, Lymphatic system, COVID-19, Cancer, Radiation-induced lung injury, SERM, Vaccine, Risk, Survival, Goserelin, Breast, DCT, Letter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Incidence, Patent, Lung cancer, Health, ER, Growth, Neoplasm, Woman, 1836 U.S. Patent Office fire, Pharmacotherapy, Axis, Degenerative disease, Therapy, MBD, Pharmaceutical industry, Medical imaging, Atossa

SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces the issuance of the following Letter to Shareholders from Steven C. Quay, M.D., Ph.D., the Company’s CEO and Chairman:

Key Points: 
  • SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces the issuance of the following Letter to Shareholders from Steven C. Quay, M.D., Ph.D., the Company’s CEO and Chairman:
    2022 was a year of significant progress for Atossa.
  • We currently have Phase 2 studies ongoing in the prevention and treatment settings, both focused on areas of unmet medical need.
  • Our investment, which totaled $4.7 million and resulted in Atossa owning approximately 19% of the outstanding capital stock of DCT, closed in December 2022.
  • On behalf of the board of directors, management, and employees of Atossa Therapeutics, we thank you for your investment and continued support of our Company.

Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations

Retrieved on: 
星期三, 十二月 7, 2022
Bristol Myers Squibb, Nivolumab, Breast cancer, Hayward Medical Communications, Government, Cancer, Radiation-induced lung injury, Commercial, Booz Allen Hamilton, Marshall College, Faron Pharmaceuticals, Patient, Unisys, Therapy, Management, Pharmaceutical industry, Atossa

SEATTLE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, is pleased to announce the appointment of Eric Van Zanten as Vice President of Investor and Public Relations.

Key Points: 
  • SEATTLE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, is pleased to announce the appointment of Eric Van Zanten as Vice President of Investor and Public Relations.
  • Mr. Van Zanten brings over 25 years of corporate communications experience working within the biopharmaceutical, finance, and healthcare industries.
  • He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company.
  • Mr. Van Zanten is a graduate of Franklin and Marshall College, where he received his BA in Political Science and Government.

TorHoerman Law Attorneys Awarded $4.4 million Verdict for Plaintiffs' Suffering Popcorn Lung from Diacetyl Exposure

Retrieved on: 
星期二, 九月 13, 2022
Respiratory tract, Epidemiology, Personal protective equipment, Partnership, Toxicology, Smell, Thromboangiitis obliterans, Workplace, THL, Degenerative disease, Taste, Radiation-induced lung injury, Multimedia, Hostile witness, PPE, Butter, Insurance, Tobacco, Health insurance, Diacetyl

Diacetyl is a chemical compound, both man-made and naturally occurring in some food manufacturing processes, that mimics the taste, texture and smell of butter.

Key Points: 
  • Diacetyl is a chemical compound, both man-made and naturally occurring in some food manufacturing processes, that mimics the taste, texture and smell of butter.
  • Though Diacetyl is safe for ingestion in its natural state, it is dangerous when heated into a vapor and inhaled, potentially causing Bronchiolitis Obliterans, also known as "Popcorn Lung".
  • The THL team represented three plaintiffs with respiratory injuries from exposure to dangerous levels of diacetyl in the workplace.
  • TorHoerman Law's efforts in fighting Diacetyl exposure cases is not over.

Registration Now Open for Tribe Public’s Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022

Retrieved on: 
星期一, 八月 22, 2022
COVID-19, Breast cancer, Therapy, SAN, Awareness, Infection, Million Pound Menu, CFO, GLOBE, Nasdaq, GC, ATOS, Q&A, Radiation-induced lung injury, Pharmaceutical industry, Atossa, Tribe

Once registered, Tribe members may then send their questions for Atossas management to [email protected] .

Key Points: 
  • Once registered, Tribe members may then send their questions for Atossas management to [email protected] .
  • Tribe members primarily include Institutions, Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media.
  • Tribe Members are encouraged to express their interest in speakers at the Tribe Public website via the Tribes FREE Wish List process.
  • Visit Tribe Publics Website http://www.tribepublic.com/ to join the Tribe and express your interests today.

Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Retrieved on: 
星期四, 七月 28, 2022
Severe acute respiratory syndrome coronavirus 2, Infection, ATOS, GLOBE, Liu v. Securities and Exchange Commission, Trial of the century, CEO, Forward-looking statement, Radiation, Incidence, Risk, Therapy, Safety, COVID-19, Esophageal cancer, Cancer, Clinical trial, Radiation-induced lung injury, FDA, Lung cancer, Security (finance), Patient, Nasdaq, Alveolar soft part sarcoma, Breast, Breast cancer, Form 10-K, Vaccine, Pharmaceutical industry, Medical imaging, Atossa, Part

Part C of the study involved administering the two drugs in succession in healthy volunteers.

Key Points: 
  • Part C of the study involved administering the two drugs in succession in healthy volunteers.
  • The study originally included a Part D which was designed to assess the effects of the treatment regimen in hospitalized COVID-19 patients with moderate illness.
  • For example, radiation treatment can lead to radiation induced lung injury, which is poorly treated with current therapies and is often irreversible.
  • The Phase 1/2a study in Australia and other clinical studies must be successfully completed and regulatory approvals must be obtained before AT-H201 can be commercialized.

Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites

Retrieved on: 
星期三, 五月 18, 2022
Research, Infectious Diseases, Hospitals, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, Infection, Department, Inflammation, Risk, Degenerative disease, Pulmonary fibrosis, Contract, Radiation, Research, Doctor of Philosophy, National Institute, Patient, National Institute of Allergy and Infectious Diseases, Survivor, Quality of life, Human services, Lung cancer, Clinical trial, COVID-19, Trial of the century, BIO, NIH, Radiation burn, NYU Langone Health, University, Attention, Injury, Radiation-induced lung injury, Cancer, Humanetics, Montefiore Medical Center, United States Department of Health and Human Services, Pharmaceutical industry

Humanetics Corporation (Humanetics) has added two additional clinical sites to its long-haul COVID-19 study, which is focused on patients who were treated for severe COVID-19 and face the possible risk that their respiratory complications will lead to long-term impairment of lung function.

Key Points: 
  • Humanetics Corporation (Humanetics) has added two additional clinical sites to its long-haul COVID-19 study, which is focused on patients who were treated for severe COVID-19 and face the possible risk that their respiratory complications will lead to long-term impairment of lung function.
  • These sites join existing sites at NYU Langone and the Houston Methodist Research Institute.
  • The clinical study is designed to evaluate the ability of Humanetics new drug, BIO 300, to mitigate long-term pulmonary damage.
  • The primary endpoint of the trial is 12 weeks after the start of dosing and patients will be followed for one year.

Humanetics Corporation Adds Two New Experts to its Board

Retrieved on: 
星期二, 十月 26, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MD, United States Department of Defense, Research, CFO, NDAS, Radiation, Inflammation, Cancer, BIO, Drug development, LLM, MBA, History, Health, Patient, Food, Regulation of tobacco by the U.S. Food and Drug Administration, Pneumonitis, Pulmonary fibrosis, Clinical trial, Board, CEO, Sangamo Therapeutics, COVID-19, Radiation exposure, Radiation-induced lung injury, Degenerative disease, Traction, Doctor of Philosophy, Pulmonary toxicity, Pharmaceutical industry

Humanetics Corporation (Humanetics), a clinical-stage pharmaceutical company pioneering radiation countermeasures, adjuvant oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of Dr. Karen Smith and Mr. Timothy Morris to the Companys Board of Directors.

Key Points: 
  • Humanetics Corporation (Humanetics), a clinical-stage pharmaceutical company pioneering radiation countermeasures, adjuvant oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of Dr. Karen Smith and Mr. Timothy Morris to the Companys Board of Directors.
  • Dr. Smith has held various President, CEO, Global Head of R&D, and Chief Medical Officer roles over the past 15 years.
  • She is currently a member of the board for Acceleron Pharmaceuticals, Sangamo Therapeutics, Antares Pharma, and Capstan Therapeutics.
  • We are thrilled to welcome Dr. Smith and Mr. Morris to the Humanetics Board of Directors, said Ronald J. Zenk, President and CEO of Humanetics.